Outlook Therapeutics reports adjusted Q1 EPS (22c), consensus (17c)

“Lytenava is demonstrating increasing adoption in Europe following our initial launches, with growing demand and quarter-over-quarter unit sales growth,” said Bob Jahr, Chief Executive Officer of Outlook Therapeutics (OTLK). “Building on this momentum, we are actively working towards launching into additional EU markets in the near term, following our January launch into Austria, as part of a broader regional expansion strategy.”